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Abstract
Background: To control multidrug resistant tuberculosis (MDR-TB), the drug susceptibility profile is needed to guide 
therapy. Classical drug susceptibility testing (DST) may take up to 2 to 4 months. The GenoType® MTBDRplus test is a 
commercially available line-probe assay that rapidly detects Mycobacterium tuberculosis (MTB) complex, as well as the 
most common mutations associated with rifampin and isoniazid resistance.
We assessed sensitivity and specificity of the assay by using a geographically representative set of MTB isolates from the
South of Vietnam.
Methods: We re-cultured 111 MTB isolates that were MDR, rifampin-resistant or pan-susceptible according to 
conventional DST and tested these with the GenoType® MTBDRplus test.
Results: By conventional DST, 55 strains were classified as MDR-TB, four strains were rifampicin mono-resistant and 52 
strains were susceptible to all first-line drugs. The sensitivity of the GenoType® MTBDRplus was 93.1% for rifampicin, 
92.6% for isoniazid and 88.9% for the combination of both; its specificity was 100%. The positive predictive value of the 
GenoType® MTBDRplus test for MDR-TB was 100% and the negative predictive value 90.3%.
Conclusions: We found a high specificity and positive predictive value of the GenoType® MTBDRplus test for MDR-TB 
which merits its use in the MDR-TB treatment program in Vietnam.
Background
Tuberculosis (TB) is an important disease in developing
countries [1]. A major concern is the occurrence of multi-
drug resistant (MDR) TB [2] which is characterized by
resistance to both rifampicin and isoniazid (INH). MDR-
TB is difficult to treat and associated with increased
treatment failures and relapses. In patients with previ-
ously untreated pulmonary TB, inappropriate treatment
may lead to selection for bacteria with drug resistance
associated mutations [3].
Vietnam ranks 14th among the countries with the high-
est burden of TB; the incidence of TB is highest in the
southern part of the country [1]. In 2005, South Vietnam
notified 29,789 new smear positive cases yielding an esti-
mated prevalence of 92.8 per 100,000 (NTP, unpublished
data, 2006). M. tuberculosis resistance to INH is common
(16-25% among new patients) [4,5]. Among patients
experiencing a first episode of TB these two studies
reported MDR-TB rates of 2 and 4%, and of 23% and 27%
among previously treated patients, respectively [4,5],
whereas 80% chronic patients had MDR-TB [6]. Geneti-
cally, approximately half of the strains belongs to the
East-African Indian clade whereas the other half are of
the Beijing genotype, which was found to be strongly
associated with (multi-)drug resistance [7,8].
To control MDR-TB, drug resistance patterns should be
available to guide the therapy of the patient. However,
phenotypic drug susceptibility testing (DST) is a time-
consuming process because it requires culturing, which
may take up to two months or longer. As long as no DST
results are available, the patient will be treated with stan-
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dard first-line anti-TB drugs. Rapid diagnosis of MDR-TB
will permit an earlier start with second-line drug treat-
ment for patients with MDR-TB and may thus decrease
the risk of treatment failure, relapse, amplification of DR,
and continuing transmission of MDR-TB.
The vast majority of resistance to rifampicin is caused
by mutations located in the 81-bp hotspot region of the
rpoB gene [9]. Mutations conferring resistance to INH are
located at several genomic loci (katG, inhA and  kasA)
[10-14]. Varying by geographic area, 50 to 100% of INH
resistant strains has mutations in codon 315 of the katG
gene or in the promoter region of the inhA  gene
[13,15,16].
The GenoType® MTBDRplus  assay (Hain Lifescience,
Nehren, Germany) is a commercially available assay that
combines detection of MTB complex with prediction of
resistance to rifampicin and INH. In the assay a multiplex
PCR is followed by hybridization of the obtained DNA
amplicons to membrane-bound probes. The assay com-
bines detection of MTB complex with detection of muta-
tions in the 81-bp hotspot region of rpoB, at codon 315 of
the katG gene and in the inhA promoter region. It was
found to have high sensitivity and high specificity for
rifampicin and INH resistance and performs well when
applied directly to AFB smear-positive sputum speci-
mens [15,17-20]. A recent meta-analysis pooled all these
studies and calculated pooled sensitivity and specificity
rates of 99% (95% confidence interval (CI), 96%-100%)
and 99% (95% CI, 98%-100%) respectively for rifampicin
resistance, and of 96% (93-98%) and 100% (99-100%),
respectively for isoniazid resistance [21].
In June 2008, the World Health Organization (WHO)
endorsed the use of molecular line-probe assays for
MDR-TB screening [22], and the GenoType® MTBDRplus
assay has since been introduced for routine practice in
various countries [15,17-20,23]. The WHO recommends
that before using the assay in routine TB treatment and
control, the performance of the assay in relation to the
locally circulating M. tuberculosis bacteria should be vali-
dated [22].
The National Tuberculosis Control Program of Viet-
nam intends to use this test in support of Programmatic
Management of DR-TB (PMDT) on sputum specimens of
all MDR-TB suspects (i.e., those failing category 1 treat-
ment and those being smear-positive after 3 months of
category 2 treatment). The Genotype® MTBDRplus assay
will be used to select patients with rifampicin resistant
isolates for PMDT. Therefore, we assessed the test's sensi-
tivity and specificity in diagnosing MDR-TB at the labo-
r a t ory of  P ha m  N g oc T hac h H os pita l (P NT H) using  a
geographically representative set of M. tuberculosis iso-
lates with known phenotypic resistance patterns from the
South of Vietnam.
Methods
Study population
We selected MTB isolates from the latest nationwide TB
drug resistance survey (DRS) in Vietnam conducted in
2004-2005. This survey was carefully designed as to cover
all geographical parts of Vietnam and the set of samples
thus provided a national estimate of drug resistance for
Vietnam. DST was done by the two national reference
laboratories, one of which was at PNTH in Ho Chi Minh
City. The DRS was part of the WHO/IUATLD Global
Project on TB Drug Resistance Surveillance and followed
WHO guidelines [24]. PNTH's laboratory participates in
an annual international proficiency study on DST
together with laboratories in Korea and Australia, with
results that are concordant to those of other laboratories
for more than 95% of the tests.
Complete DST results were available for 1,826 patients
with smear-positive TB from 80 different TB clinics
throughout the country. Of these, 1,044 (57%) specimens
were collected in the South of Vietnam and tested in
PNTH (910 from new patients and 134 from previously
treated patients). Sputum specimens were processed
according to standard procedures [24]. After centrifuga-
tion, sediment was inoculated on Löwenstein-Jensen (LJ)
medium and incubated at 37°C for 4 to 8 weeks followed
by species identification of culture-positive samples. DST
for isoniazid (0.2 μg/ml), streptomycin (4 μg/ml), etham-
butol (2 μg/ml), and rifampicin (40 μg/ml) was performed
using LJ media following the proportion method [25].
Isolates from all 30 new and 29 re-treatment cases that
were either identified as MDR-TB (n = 55) or resistant to
rifampicin (n = 4) by phenotypic DST were included in
this study. In addition, from the isolates that were suscep-
tible to all tested first-line drugs from new and re-treat-
ment patients, we randomly selected 52 isolates, so that
the total number of tested strains was 111.
GenoType® MTBDRplus testing
GenoType® MTBDRplus  testing was performed blinded
from the phenotypic DST results. The selected MTB iso-
lates were re-cultured from the -70°C freezer and sub-
jected to the GenoType® MTBDRplus test according to
the manufacturer's recommendations http://www.hain-
lifescience.de. By multiplex PCR the rpoB, katG and inhA
genes were amplified and the resulting biotin-labeled
amplicons were hybridized to DNA probes bound to
membrane strips. Hybridization was detected by addition
of a streptavidin/alkaline phosphatase (AP) conjugate and
an AP mediated staining reaction. For each gene, the
GenoType® MTBDRplus  assay tests for presence of so-
called wild-type (WT) and mutant (MUT) probes, the
first comprising the most important resistant areas of the
respective genes and the second some of the most com-
mon resistance mediating mutations. Next to that, theHuyen et al. BMC Infectious Diseases 2010, 10:149
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TUB zone hybridizes with amplicons generated from all
members of the Mycobacterium complex and can thus
serve for species identification. The membrane-bound
DNA probes included eight rpoB wild-type probes, four
rpoB mutant probes (with D516V, H526Y, H526D, and
S531L mutations), one katG wild-type probe, two katG
mutant probes (with S315T1 and S315T2 mutations), two
inhA  wild-type probes and four inhA  mutant probes
(with C15T, A16G, T8C, and T8A mutations) [26]. Fol-
lowing the manufacturer's instructions http://www.hain-
lifescience.de, susceptibility to isoniazid and rifampicin
was defined as hybridization to all the wild type probes
and no hybridization to the mutant probes. A strain that
revealed hybridization to both a mutant probe and to the
corresponding wild type probe was considered to repre-
sent a heterogeneous population of bacteria or a mixed
infection of a sensitive and a resistant strain.
Species identification
M. tuberculosis was identified by smear microscopy fol-
lowed by a positive niacine reaction [27]. Further species
identification was performed using Innolipa Mycobacte-
ria v2 (Innogenetics, Gent, Belgium) if a discrepancy was
found between initial species identification and results
from the GenoType® MTBDRplus assay (i.e., no hybridiza-
tion with the TUB band).
DNA fingerprinting and sequencing
In order to identify possible cases of mixed infection,
spoligotyping [28] and IS6110 restriction fragment length
polymorphism (RFLP) [29] were applied to single colo-
nies growing on standard culture medium and medium
supplemented with tuberculostatics. DNA patterns were
scanned and analysed by using Gelcompar software
(Applied Maths, Sint-Martens-Latum, Belgium) as previ-
ously described [30]. The Beijing genotype was defined
by spoligotyping as any isolate without Direct Repeat
spacers 1-34 and the presence of ≥3 of the spacers 35-43
[31]. Other genotypes were defined as described by
Brudey et al. [32], including the Vietnam genotype (EAI-
VNM) that belongs to the East African Indian genotype
family of M. tuberculosis and is the most frequent geno-
type in this study site [8].
Sequencing of the rifampin resistance-determining
region (RRDR) region of the rpoB gene was performed for
strains that had discordant results for rifampicin accord-
ing to conventional DST and the GenoType® MTB-
DRplus test. The 350 bp fragment of the rpoB gene was
amplified using outer primers RPOBF (5'-
GGGAGCGGATGACCACCCA3') and RPOBR (5'-
GCGGTACGGCGTTTCGATGAAC-3'). The primers
were designed using Primer Express version 2.0 software
(Applied Biosystems Inc, Foster City, CA, USA) [33].
Ethical approval
The study protocol was approved by the Research Board
of Pham Ngoc Thach hospital. Since this study used
stored isolates with known drug resistance patterns and
no additional procedures on the patients were involved,
individual informed consent was not obtained.
Statistical Methods
Data were double entered in EpiData version 3.1 http://
www.epidata.dk by two separate study assistants. Dis-
crepancies were checked against the crude data. Chi-
squared tests were performed using Epi Info version 6.04
http://www.cdc.gov/epiinfo/. Results were considered
significant at P < 0.05.
Results
Concordance between conventional DST and GenoType® 
MTBDRplus assay
Of 111 isolates tested, there was one MDR strain that
lacked the TUB band. Although this strain was earlier
identified as M. tuberculosis, further species identifica-
tion identified the strain as M. avium-intracellulare
(MAIS). Spoligotyping after re-culturing this isolate
showed that it was a mixture of M. tuberculosis and
MAIS. Since the GenoType® MTBDRplus assay did not
identify this strain as MDR-TB, all analyses describing the
assay's performance include 110 isolates, of which 58
were resistant to rifampicin by conventional DST.
Based on phenotypic DST, 54 strains were MDR-TB,
four strains were rifampicin mono-resistant and 52
strains were susceptible to all first-line drugs. Consider-
ing the phenotypic DST method as the gold standard, the
GenoType® MTBDRplus test correctly identified 48 of 54
MDR-TB strains (88.9%, 95% CI: 77.4-95.8%); 54 of 58
rifampicin resistant strains (93.1%, 95% CI: 83.3-98.1%);
50 of 54 INH resistant strains (92.6%, 95% CI: 82.1-
97.9%); and all susceptible strains (100%, 95% CI: 93.2-
100%). The specificity for detecting MDR-TB was 100%.
The overall concordance of the GenoType® MTBDRplus
test and phenotypic DST was 94.5% (104/110). Sensitivi-
ties, specificities and predictive values are listed in Table
1.
Sequencing the RRDR region of the rpoB gene of the
four strains with discordant results for rifampicin
revealed that one strain possessed the H526L mutation
which is not present on the membrane strips; in the three
remaining strains no mutations were detected in the rpoB
gene.
Frequency of drug resistance associated mutations
Mutation patterns produced by the GenoType®  MTB-
DRplus test are displayed in Table 2. Among the 54 RIF
resistant TB strains detected by this test, the frequency of
rpoB mutations was: 27 S531L (50%), 6 H526Y (10.9%), 3Huyen et al. BMC Infectious Diseases 2010, 10:149
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D516V (5.5%), 1 H526D (1.8%), 7 missing WT2 (12.7%),
10 missing WT3 (18.1%), 6 missing WT4 (10.9%), 14
missing WT7 (25.5%), 26 missing WT8 (48%), and no
case missing WT1, WT5 or WT6.
Among 50 INH resistant TB strains as identified by the
GenoType® MTBDRplus test, katG mutations occurred in
43 (86%) and inhA mutations in 9 strains (18%). Two of
the 43 (5%) strains with a katG codon 315 mutation had
an additional mutation in the inhA promoter region. The
most frequently observed katG  mutation was katG
S315T1 (in 38 of 43 strains, 88.4%), whereas katG S315T2
(2.3%) and unknown mutations (i.e., no hybridization to
the katG WT nor to either of the mutation probes, 9.3%)
occurred less frequently. All 9 strains with a mutation in
the inhA promoter region had an inhA C15T mutation
(Table 2).
Detection of mixed bacterial populations
With this rapid assay four possible mixtures were
detected, although one of these was not identified by the
Table 1: The sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) and 95% 
confidence intervals of the GenoType® MTBDRplus assay on 111 M. tuberculosis cultures isolates in the South of Vietnam.
Rifampicin Isoniazid Multi drug resistance
Sensitivity 93.1% (83.3-98.1) 92.6% (82.1-97.9) 88.9% (77.4-95.8)
Specificity 100% (93.2-100) 100% (93.6-100) 100% (93.6-100)
PPV 100% (93.4-100) 100% (92.9-100) 100% (92.6-100)
NPV 92.9% (82.7-98.0) 93.3% (83.8-98.1) 90.3% (80.1-96.4)
Table 2: Mutation patterns following from the GenoType ® MTBDRplus assay.
rpoB mutations katG mutations inhA mutations Frequency Proportion
D516V S315T1 -- 1 0.9
D516V unknown * -- 1 0.9
D516V -- C15T 1 0.9
H526D S315T1 -- 1 0.9
H526Y S315T1 -- 5 4.6
S531L unknown * -- 2 1.8
S531L S315T1 C15T 1 0.9
S531L S315T1 -- 16 14.6
S531L S315T2 -- 1 0.9
S531L -- C15T 4 3.6
S531L -- -- 2 1.8
H526Y + S531L -- -- 1 0.9
unknown * S315T1 -- 13 11.8
unknown * -- -- 3 1.8
unknown * unknown * C15T 1 0.9
unknown * -- C15T 1 0.9
-- S315T1 -- 1 0.9
-- -- C15T 1 0.9
Total number of strains with any mutations 56 50.9
-- -- -- 54 49.1
Total number of strains 110 100
* unknown mutation: no hybridization to one or more of the wild type probes nor to any of the mutation probes.Huyen et al. BMC Infectious Diseases 2010, 10:149
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assay as M. tuberculosis due to a lacking TUB band and
was later identified to contain MAIS. These four pheno-
typically rifampicin resistant isolates were demonstrated
to carry mutations in the rpoB gene and/or in the katG
gene or the inhA  promoter region, but did not lack
hybridization on any of the wild type probes. By using
DNA fingerprinting one of these isolates was confirmed
to be a mixture of two MTB strains (spoligotype T1 and
an undefined type; RFLP type T1 and Beijing), and the
isolate lacking the TUB band (number 12647) was identi-
fied as a mixture of a MTB strain (spoligotype U) and a
non-tuberculous mycobacterium (note that spoligotyping
yielded a weak signal for M. tuberculosis for one single
colony culture of this isolate) (T able 3, Figure 1). In the
two remaining samples mixed bacterial populations could
not be detected. After spoligotyping which revealed no
differences as it has a very low resolution among Beijing
strains, we also performed IS6110 RFLP typing on single
colony cultures of each of these two samples and found
they all had identical banding patterns (Table 3).
Discussion
In this study, the GenoType® MTBDRplus assay correctly
identified 93.1%, 92.6% and 88.9% of the rifampicin, INH
and combined resistance (MDR), respectively and had
100% specificity for each. The sensitivity of detection of
rifampicin resistance was similar to that reported from
Germany, Italy, Finland, France, Denmark, Turkey and
Taiwan (92-100%, p > 0.05) [15,17-20,26,34,35]. The Gen-
oType® MTBDRplus assay failed to detect four (6.8%) of
the rifampicin resistant strains in our study, which was
caused either by a rare mutation which is not present on
t h e  s t r i p s  ( n  =  1 )  o r  b y  p r o b a b l e  m u t a t i o n s  i n  o t h e r
genomic regions of the rpoB gene (n = 3). The sensitivity
for detection of isoniazid resistance in our study was
91.2%, which was similar to reports from Germany, Fin-
land, Denmark and Taiwan (84 - 100%, p > 0.05) [15,17-
20,26,34,35], but higher than reported from Turkey, Italy,
France and the Caribbean (35-73%, P < 0.05)
[17,18,20,36]. For MDR-TB the sensitivity of the test was
somewhat lower than reported from other research [21].
The distribution of mutations identified in our study is
significantly different from that reported from other con-
tinents. We found that the S531L mutation in the rpoB
gene occurred most frequently (50%) among rifampicin
resistant strains. This mutation occurred even more fre-
quently in a collection of isolates from South Africa
(70.5%, p = 0.014) [23]. In our study only 36 (66.7%)
MDR-TB strains had a mutation that could be identified
by one of the four rpoB mutant probes present on the
strip, whereas this was much higher in South Africa (91%
(81/89)) [23]. Thus, the assay performs better detecting
rpoB specific mutations that confer rifampicin resistance
i n  S o u t h  A f r i c a  t h a n  i n  V i e t n a m .  F o r  I N H  r e s i s t a n c e ,
mutations in the katG gene were by far most common
(86%) and the S315T1 mutation was found most fre-
quently (88.4%) in our population. From South Africa,
Van Rie et al [37] reported similar results, whereas Bar-
n a r d  a n d  c o l l e a g u e s  [ 2 3 ]  r e p o r t e d  t h a t  t h i s  m u t a t i o n
occurred less frequently (37.6%; p = 0.01). In our study
18% of INH resistant MTB strains carried a mutation in
the  inhA  promoter region (invariably C15T) which is
considerably lower than the 40% reported in Barnard's
study (p = 0.007). It should be noted that we only tested
MDR-TB isolates, whereas Barnard's study also included
INH monoresistant strains and MDR-TB may be primar-
ily associated with katG mutations that generally confer
high levels of INH resistance [38].
The GenoType® MTBDRplus assay can detect mixtures
of drug resistant and drug susceptible bacterial popula-
tions. In this study four mixtures were found: three mix-
tures of M. tuberculosis strains and one mixture of a M.
Figure 1 Patterns of multiple Mycobacterium spp. infections as obtained by RFLP and spoligotyping techniques. The first three isolates have 
only one band by RFLP (non-Beijing) and spoligotype T1; the 4th sample is a mixture of Beijing genotype (as obtained by RFLP) and spoligotype T1. 
The 5th sample has no RFLP banding pattern and an undefined spoligotype, whereas for the last three isolates no banding patterns were found by 
RFLP and spoligotyping, probably as a result of the presence of non-tuberculous mycobacteria (NTM).
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tuberculosis strain and an M. avium complex strain. This
indicates that even in a high prevalence area like Vietnam
a minor proportion of the TB cases is caused by a mixture
of non-tuberculous mycobacteria and MTB. The Geno-
Type® MTBDRplus assay may not be sensitive enough to
be used for species identification in case of mixed bacte-
rial populations, since the M. tuberculosis and M. avium
mixture revealed no TUB band.
Mixed infections were confirmed by typing a limited
number of single colony cultures by spoligotyping and
RFLP. In two samples that seemed to consist of a mixture
when tested with the GenoType® MTBDRplus assay, pres-
ence of a mixed infection could not be confirmed which
could have been the result of testing only a limited num-
ber of single colony cultures.
With the 100% specificity of the GenoType®  MTB-
DRplus assay to detect MDR in M. tuberculosis isolates,
no patient would be inappropriately treated with category
4 (MDR-TB) treatment if this test would be used in rou-
tine for rapid MDR-TB diagnosis. On the other hand,
6.9% of patients would not receive appropriate category 4
treatment (which is based on detection of rifampicin
resistance) if identification of MDR-TB patients is done
using only the GenoType® MTBDRplus test.
Conclusions
Overall, the GenoType® MTBDRplus test is reliable, rapid
and easy to perform for the simultaneous detection of
rifampicin and INH resistance in M. tuberculosis. With
high sensitivity for detection of rifampin resistance and
high specificity for MDR, we conclude that this test
strongly facilitates adequate treatment of MDR-TB
patients, long before the results of conventional DST are
available. Because discordance still exists between the
conventional and molecular approach of DST and sus-
ceptibility of bacteria to drugs is defined as inhibition of
growth, we recommend that the GenoType® MTBDRplus
test should serve as an early guidance of therapy, which
should be followed by a phenotypic DST confirmation for
all suspected MDR-TB patients. Incorporation of the
molecular test in the National Tuberculosis Program is an
important step forward in the rapid diagnosis of MDR-
TB among suspected patients in the PMDT program. The
application of the molecular test directly to clinical mate-
rial with sufficient bacteria will further speed up the turn-
around time of the rapid diagnosis of MDR-TB and will
be the next step of implementation.
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